Wave Plans To Pursue Accelerated Approval For Huntington’s Drug
NfL Concern From Early Trial May Be Overblown
The biotech said it plans to engage with regulators before the end of the year for the Takeda-partnered antisense oligonucleotide, WVE-003, to discuss a pivotal trial that would support accelerated approval.
